BOSTON, March 30, 2026 -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not...
Arthur Klausner will be a panelist at the New York Biotechnology Association's Annual Meeting
News | 04. 17. 2006
